Premenstrual syndrome.
The premenstrual syndrome (PMS) is a major clinical entity afflicting a large segment of the female population. Available information are descriptive in nature and the etiology of this syndrome remains unclear. In this review, both biochemical and psychosocial elements of the syndrome have been explored in an effort to redefine the pathophysiology of this seemingly multifactorial psychoneuroendocrine dysfunction. We propose that luteal phase sensitivity to and subsequent withdrawal from the central effects of the neuropeptides beta-endorphin and alpha-melanocyte-stimulating hormone result in a cascade of neuroendocrine changes within the brain-hypothalamus-pituitary complex. Modulation of neurotransmitter function by these peptides may produce alterations in mood and behavior as well as enhance pituitary release of prolactin and vasopressin. Variable gonadal steroid modulation of these responses from subject to subject likely accounts for the heterogeneous clinical manifestations of the PMS.
D000328:Adult; D001361:Avitaminosis; D003276:Contraceptives, Oral / Q000494:pharmacology; D004723:Endorphins / Q000502:physiology; D004967:Estrogens / Q000502:physiology; D005260:Female; D006728:Hormones / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000150:complications; D007003:Hypoglycemia / Q000150:complications; D009074:Melanocyte-Stimulating Hormones / Q000502:physiology; D011293:Premenstrual Syndrome / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control / Q000523:psychology; D011374:Progesterone / Q000172:deficiency; D013577:Syndrome; D014882:Water-Electrolyte Balance
D003276:Contraceptives, Oral; D004723:Endorphins; D004967:Estrogens; D006728:Hormones; D011374:Progesterone; D009074:Melanocyte-Stimulating Hormones